2,2'-dithiodiethanesulfonic acid has been researched along with mesna in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (32.14) | 18.7374 |
| 1990's | 10 (17.86) | 18.2507 |
| 2000's | 18 (32.14) | 29.6817 |
| 2010's | 10 (17.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leeuwenkamp, OR; Neijt, JP; Pinedo, HM; van der Vijgh, WJ | 2 |
| Goren, MP; Li, JT; Lyman, BA | 1 |
| Al-Safi, SA; Maddocks, JL | 1 |
| Graham, MI; Jones, MS; Shaw, IC | 1 |
| Kohl, M; Reuther, H; Wildenauer, DB | 1 |
| James, CA; Rogers, HJ | 1 |
| Habs, M; Schmähl, D | 1 |
| Brock, N; Pohl, J | 1 |
| James, CA; Mant, TG; Rogers, HJ | 1 |
| Shaw, IC; Weeks, MS | 1 |
| Graham, MI; Shaw, IC | 1 |
| Petru, E; Schmähl, D | 1 |
| Amano, T; Ikeuchi, I | 1 |
| Habs, MR; Schmähl, D | 2 |
| Habs, M; Schmähl, D; Tacchi, AM | 1 |
| Hermans, JM; Hutten, TJ; van der Drift, C; Vogels, GD | 1 |
| Brock, N; Stekar, J | 1 |
| Ormstad, K; Uehara, N | 1 |
| Ansorge, S; Brandis, M; Mohrmann, M; Schönfeld, B | 1 |
| al-Rawithi, S; el-Yazigi, A; Yusuf, A | 1 |
| Kurowski, V; Wagner, T | 1 |
| al-Rawithi, S; el-Yazigi, A; Ernst, P; Legayada, E; Raines, DA | 1 |
| Goren, MP; Hsu, LC; Li, JT | 1 |
| Cao, S; Haridas, K; Hausheer, FH; Kanter, P; Martinez, N; Murali, D; Petluru, P; Reddy, D; Rustum, YM; Saxe, JD; Seetharamulu, P; Yao, S; Zhao, M; Zukowski, A | 1 |
| Brade, WP; Bush, DA; Goren, MP; Houle, JM; Li, JT; Newman, CE | 1 |
| de Koning, PE; van der Vijgh, WJ; Verschraagen, M; Welink, J; Zwiers, TH | 1 |
| Senior, K | 1 |
| Boven, E; Erkelens, CA; Hausheer, FH; Hulscher, TM; Pinedo, HM; van der Vijgh, WJ; Verschraagen, M | 1 |
| Hausheer, F; Murphy, M; Pendyala, L; Schwartz, G; Smith, P; Zdanowicz, J | 1 |
| Donker, MG; Reinhoud, NJ; Torun, E; Van der Vijgh, WJ; Verschraagen, M; Zwiers, TH | 1 |
| Hausheer, FH; Kedde, MA; Van Der Vijgh, WJ; Verschraagen, M | 1 |
| An, D; Church, JS; Garzena, F; Li, YS; Wang, Y; Zhang, Z | 1 |
| Boven, E; Hausheer, FH; Van der Vijgh, WJ; Verschraagen, M; Zegers, I | 1 |
| Bain, SH; Ding, D; Hamilton, SE; Hausheer, FH; Kochat, H; Leverett, BD; Parker, AR; Petluru, PN; Saxe, JD; Yao, S | 1 |
| Berkhof, J; Boven, E; Hausheer, FH; Ruijter, R; van der Born, K; van der Vijgh, WJ; Verschraagen, M | 1 |
| GUENTERT, G | 1 |
| Reilly, RT | 1 |
| Boven, E; Erkelens, CA; Hausheer, FH; Torun, E; van der Vijgh, WJ; Verschraagen, M | 1 |
| Galanski, M; Jakupec, MA; Keppler, BK | 1 |
| Bast, A; Boven, E; Hausheer, FH; Torun, E; van der Vijgh, WJ; Verschraagen, M | 1 |
| Boven, E; Giaccone, G; Ruijter, R; van der Vijgh, WJ; van Groeningen, CJ; Verschraagen, M; Westerman, M; Zegers, I | 1 |
| Bolger, M; Dunphy, F; Edelman, MJ; Green, MR; Gu, L; Hoffman, P; Khatri, J; Miller, AA; Vokes, EE; Wang, XF | 1 |
| Bastings, MM; Meijer, EW; Merkx, M; van Baal, I | 1 |
| Ayala, PY; Chen, X; Ding, D; Hausheer, FH; Huang, Q; Kochat, H; Parker, AR; Petluru, PN; Shanmugarajah, D | 1 |
| Chen, X; Hausheer, FH; Huang, Q; Kochat, H; Leverett, BD; Parker, AR; Petluru, PN; Shanmugarajah, D | 1 |
| Ayala, PY; Chen, S; Chen, X; Hausheer, FH; Huang, Q; Jair, KW; Kochat, H; Parker, AR; Petluru, PN; Shanmugarajah, D | 1 |
| Fukuoka, M; Hausheer, F; Kudoh, S; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Ohashi, Y; Takeda, K; Yamamoto, N; Yoshimura, N | 1 |
| Hausheer, FH; Kochat, H; Parker, AR; Petluru, PN; Wu, M; Zhao, M | 1 |
| Ayala, PY; Chen, X; Ding, D; Hausheer, FH; Huang, Q; Kochat, H; Leverett, BD; Parker, AR; Petluru, PN; Shanmugarajah, D | 1 |
| Cutler, MJ; Dresser, GK; Freeman, DJ; Kim, RB; Leake, BF; Meyer Zu Schwabedissen, HE; Tirona, RG; Urquhart, BL; Velenosi, TJ | 1 |
| Bodalia, A; Cutler, MJ; Freeman, DJ; House, AA; Urquhart, BL; Velenosi, TJ | 1 |
| Ayala, PY; Badger, J; Hausheer, FH; Jair, K; Kochat, H; Leverett, BD; Logan, C; Nienaber, VL; Parker, AR; Petluru, PN; Sridhar, V | 1 |
| Barton, S; Nabhani-Gebara, S; Peron, JM; Salman, D; Swinden, J | 1 |
| Bechtel, SA; Bryan, JN; Bryan, ME; Flesner, BK; Grubb, L; Hausheer, F; Henry, CJ; Lattimer, JC; Selting, KA; Tate, DJ | 1 |
5 review(s) available for 2,2'-dithiodiethanesulfonic acid and mesna
| Article | Year |
|---|---|
Mesna--a short review.
Topics: Cystitis; Expectorants; Humans; Mercaptoethanol; Mesna; Neoplasms | 1987 |
Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Interactions; Humans; Kidney Diseases; Mesna; Platinum Compounds; Protective Agents; Sulfhydryl Compounds | 1998 |
New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
Topics: Animals; Clinical Trials, Phase I as Topic; Computer Simulation; Drug Design; Humans; Lethal Dose 50; Mesna; Models, Chemical; Neurotoxicity Syndromes; Protective Agents | 2003 |
BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
Topics: Animals; Antiemetics; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Mesna; Structure-Activity Relationship; Vomiting | 2004 |
The effect of cytoprotective agents in platinum anticancer therapy.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Glutathione; Humans; Mesna; Neoplasms; Platinum Compounds; Protective Agents; Thioctic Acid; Vitamin E | 2004 |
9 trial(s) available for 2,2'-dithiodiethanesulfonic acid and mesna
| Article | Year |
|---|---|
Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
Topics: Administration, Oral; Adult; Female; Humans; Injections, Intravenous; Kinetics; Male; Mercaptoethanol; Mesna; Middle Aged | 1987 |
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged | 1997 |
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Topics: Administration, Oral; Adult; Biological Availability; Creatinine; Cross-Over Studies; Humans; Injections, Intravenous; Male; Mesna; Protective Agents | 1998 |
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Ascites; Chromatography, High Pressure Liquid; Cisplatin; Electrochemistry; Half-Life; Humans; Male; Mesna | 2003 |
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Mesna; Middle Aged; Platinum; Prospective Studies; Tissue Distribution | 2003 |
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dehydration; Female; Humans; Kidney Diseases; Male; Mesna; Middle Aged; Neoplasms | 2005 |
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Darbepoetin alfa; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Taxoids | 2008 |
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.
Topics: Adult; Female; Glomerular Filtration Rate; HeLa Cells; Humans; Kidney; Male; Membrane Transport Proteins; Mesna; Middle Aged; Organic Anion Transporters; Probenecid; Protective Agents; Tissue Distribution; Young Adult | 2012 |
42 other study(ies) available for 2,2'-dithiodiethanesulfonic acid and mesna
| Article | Year |
|---|---|
Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
Topics: Chromatography, Ion Exchange; Cisplatin; Drug Interactions; Half-Life; Kinetics; Mesna; Thiosulfates | 1991 |
The stability of mesna in beverages and syrup for oral administration.
Topics: Administration, Oral; Beverages; Colorimetry; Drug Stability; Drug Storage; Mesna; Solutions; Syringes; Time Factors | 1991 |
Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP.
Topics: Animals; Cisplatin; Ditiocarb; Half-Life; Injections, Intraperitoneal; Injections, Intravenous; Mesna; Models, Biological; Peritoneal Cavity; Thiosulfates | 1990 |
Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.
Topics: Azathioprine; Chromatography, Thin Layer; Cyclophosphamide; Humans; In Vitro Techniques; Lymphocyte Culture Test, Mixed; Mercaptoethanol; Mesna | 1986 |
The fate of [14C]-mesna in the rat.
Topics: Animals; Carbon Radioisotopes; Immunoglobulins; Kidney; Male; Mercaptoethanol; Mesna; Rats; Rats, Inbred Strains; Serum Albumin; Tissue Distribution | 1986 |
The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
Topics: Erythrocytes; Humans; In Vitro Techniques; Ion Exchange; Kinetics; Mercaptoethanol; Mesna; Sulfates; Sulfur Radioisotopes | 1986 |
Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Half-Life; Humans; Mercaptoethanol; Mesna | 1986 |
New experimental approaches to reducing carcinogenicity in animals by modifying regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Male; Mesna; Neoplasms, Experimental; Nitrogen Mustard Compounds; Nitrosourea Compounds; Rats; Structure-Activity Relationship | 1986 |
Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Topics: Animals; Biotransformation; Cyclophosphamide; DNA; Glutathione; Ifosfamide; Kidney; Leukemia, Experimental; Mercaptoethanol; Mesna; Rats; Structure-Activity Relationship; Urinary Bladder; Urinary Bladder Neoplasms | 1986 |
Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Disulfides; Female; Humans; Male; Mercaptoethanol; Mesna; Sulfhydryl Compounds | 1987 |
Anticancer drugs: second malignancies--risk reduction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorouracil; Male; Mesna; Methotrexate; Neoplasms, Multiple Primary; Rats; Vincristine | 1987 |
Simultaneous determination of 2-mercaptoethanesulfonate and its disulfide in human urine by isotachophoresis.
Topics: Electrophoresis; Humans; Mercaptoethanol; Mesna | 1985 |
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Male; Mercaptoethanol; Mesna; Neoplasms, Experimental; Rats; Rats, Inbred Strains; Risk; Urinary Bladder Neoplasms | 1983 |
Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.
Topics: Animals; Cyclophosphamide; Male; Mercaptoethanol; Mesna; Rats; Rats, Inbred Strains; Urinary Bladder Neoplasms | 1983 |
[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
Topics: Animals; Carcinoma, Transitional Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Male; Mercaptoethanol; Mesna; Papilloma; Rats; Rats, Inbred Strains; Urinary Bladder Neoplasms | 1984 |
Analysis of coenzyme m (2-mercaptoethanesulfonic acid) derivatives by isotachophoresis.
Topics: Electrophoresis; Mercaptoethanol; Mesna | 1980 |
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Topics: Animals; Cyclophosphamide; Ifosfamide; Kidney Diseases; Mercaptoethanol; Mesna; Oxidation-Reduction; Rats; Rats, Inbred Strains | 1982 |
Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat.
Topics: Animals; Biological Transport; Glutathione; Kidney; Kinetics; Male; Mercaptoethanol; Mesna; Rats; Rats, Inbred Strains; Sulfhydryl Compounds | 1982 |
Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
Topics: Animals; Cell Line; Cells, Cultured; Cyclophosphamide; DNA; DNA Replication; Drug Combinations; Ifosfamide; Kidney Tubules; Mesna; RNA; Thymidine; Uridine | 1994 |
Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
Topics: Bone Marrow Transplantation; Chromatography, Liquid; Humans; Injections, Intravenous; Mesna; Time Factors | 1995 |
Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cystitis; Female; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Mesna | 1997 |
Reduction of dimesna to mesna by the isolated perfused rat liver.
Topics: Animals; Biotransformation; Buthionine Sulfoximine; Female; Glutathione; In Vitro Techniques; Kinetics; Liver; Mesna; Oxidation-Reduction; Perfusion; Rats; Rats, Sprague-Dawley | 1998 |
Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Half-Life; Humans; Mesna; Reproducibility of Results; Sensitivity and Specificity | 2001 |
Supercomputer-designed drug protects against chemotherapy toxicity.
Topics: Breast Neoplasms; Central Nervous System Diseases; Computer-Aided Design; Controlled Clinical Trials as Topic; Drug Design; Drug Interactions; Female; Humans; Mesna; Paclitaxel | 2000 |
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cell Division; Cisplatin; Drug Interactions; Female; Humans; Lethal Dose 50; Mesna; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Protective Agents; Radiation-Protective Agents; Transplantation, Heterologous; Weight Loss | 2002 |
Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cisplatin; Cysteine; Disulfides; Glutathione; Half-Life; Humans; Infusions, Intravenous; Kinetics; Mesna; Neoplasms; Paclitaxel; Sulfhydryl Compounds | 2003 |
Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
Topics: Animals; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Kidney; Mesna; Protective Agents; Rats; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2003 |
The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
Topics: Algorithms; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cisplatin; Disulfides; Ditiocarb; Expectorants; Glutathione; Half-Life; Kinetics; Mesna; Spectrophotometry, Atomic; Thiosulfates | 2003 |
Vibrational spectroscopic studies of mesna and dimesna.
Topics: Adsorption; Hydrogen; Hydrogen-Ion Concentration; Mesna; Molecular Conformation; Protective Agents; Spectrophotometry; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Sulfur | 2003 |
[An effective device against the dimming of specula].
Topics: Equipment and Supplies; Indoles; Mesna; Otolaryngology | 1962 |
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cisplatin; Colonic Neoplasms; Female; Humans; Injections, Intravenous; Kidney; Mesna; Neoplasms, Experimental; Protective Agents; Rats; Rats, Inbred F344 | 2004 |
Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Topics: Animals; Antineoplastic Agents; Cisplatin; Cysteine; Cytosol; Electrochemistry; Enzymes; Erythrocytes; Glutathione; Humans; Mesna; Protective Agents; Rats; Tissue Distribution | 2004 |
One-step refolding and purification of disulfide-containing proteins with a C-terminal MESNA thioester.
Topics: Mesna; Oxidation-Reduction; Protective Agents; Protein Folding; Recombinant Proteins; Ribonuclease, Pancreatic | 2008 |
Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
Topics: Buffers; Chromatography, High Pressure Liquid; Disulfides; Humans; Mesna; Phosphates; Sensitivity and Specificity; Sulfhydryl Compounds | 2009 |
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
Topics: Animals; Antineoplastic Agents; Cisplatin; gamma-Glutamyltransferase; Humans; Kidney; Mesna; Protective Agents; Swine | 2010 |
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
Topics: Allosteric Regulation; Biocatalysis; CD13 Antigens; Cisplatin; Cysteine; Dipeptides; Glutathione; Glycine; Humans; Kidney Diseases; Kinetics; Mesna; Models, Biological; Protective Agents; Recombinant Proteins | 2011 |
BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
Topics: Animals; Antineoplastic Agents; Cattle; Cisplatin; Drug Interactions; Mesna; Microtubule Proteins; Microtubules; Paclitaxel; Polymerization | 2010 |
Accumulation of BNP7787 in human renal proximal tubule cells.
Topics: Cell Line; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Kidney Tubules, Proximal; Mesna | 2011 |
Enzymatic and non-enzymatic mechanisms of dimesna metabolism.
Topics: Animals; Cell Line; Cysteine; Female; Glutathione; Homocysteine; Humans; Kidney; Liver; Mesna; Mice; Oxidation-Reduction | 2015 |
Cysteine specific targeting of the functionally distinct peroxiredoxin and glutaredoxin proteins by the investigational disulfide BNP7787.
Topics: Antineoplastic Agents; Binding Sites; Crystallography, X-Ray; Cysteine; Glutaredoxins; Homeodomain Proteins; Humans; Mass Spectrometry; Mesna; Models, Molecular; Peroxiredoxins; Protein Structure, Tertiary | 2015 |
New investigations into the stability of Mesna using LC-MS/MS and NMR.
Topics: Chromatography, Liquid; Drug Stability; Drug Storage; Hydrogen-Ion Concentration; Injections; Magnetic Resonance Spectroscopy; Mesna; Tandem Mass Spectrometry | 2016 |
Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.
Topics: Animals; Antineoplastic Agents; Blood Urea Nitrogen; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Diuresis; Dog Diseases; Dogs; Drug Therapy, Combination; Mesna; Piroxicam; Prospective Studies; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |